U.S. Health Leaders Push for Expanded Care as Overdose Risks Evolve

At the 15th Annual Rx and Illicit Drug Summit in Nashville, leading medical organizations called for stronger, more accessible treatment systems to continue progress against the nation’s overdose crisis—especially as increasingly potent synthetic substances like FYL and XYL reshape the risk landscape.

Progress Made—But the Crisis Isn’t Over

According to provisional data from the Centers for Disease Control and Prevention, overdose deaths in the U.S. dropped significantly—falling nearly 38% between October 2023 and October 2025. Despite this improvement, health leaders stress that the epidemic continues to impact millions of families nationwide.

At the summit, representatives from the American Medical Association, American Society of Addiction Medicine, and American Pharmacists Association emphasized that sustained progress depends on expanding access to affordable, evidence-based care.

Dr. Bobby Mukkamala highlighted that meaningful change requires coordinated, community-based efforts involving physicians, pharmacists, public health leaders, and policymakers working together to support individuals with opioid use disorder (OUD) and chronic pain.

Breaking Barriers to Treatment

Experts at the summit identified several urgent priorities:

• Improving collaboration across healthcare professions
• Reducing stigma surrounding substance use and pain management
• Eliminating barriers that limit access to treatment

Speakers also called for policy changes to expand addiction treatment options, including allowing qualified physicians to prescribe medications like methadone outside of traditional clinic settings. Increasing access to care for older adults and protecting patients with legitimate pain needs were also key concerns.

A recurring theme was the need to ensure that fear—whether regulatory or legal—does not prevent clinicians or pharmacies from providing appropriate care.

Policy Updates: Medicare Advantage Changes

Recent updates from the Centers for Medicare & Medicaid Services (CMS) introduced a mix of improvements and ongoing concerns for healthcare providers.

Among the positive developments:

• A 2.48% increase in average payments for Medicare Advantage plans
• New safeguards to ensure payments reflect actual patient care, not just documentation
• Continuity-of-care protections for vulnerable patients

However, several accountability measures were weakened. CMS removed certain oversight requirements and performance metrics tied to plan operations, raising concerns about reduced transparency and responsibility among insurers.

Additionally, CMS introduced a system to flag physicians as opioid “outliers” based on prescribing patterns. While intended to curb unsafe prescribing, critics—including the AMA—warn this could discourage appropriate pain treatment. An important exception was added to protect physicians treating patients in palliative or end-of-life care.

Shifting Toward More Accurate Risk Models

CMS also finalized a policy change ensuring that diagnosis codes used for risk scoring must be tied to actual care provided—such as tests or treatments. This aims to create a more accurate system where payments reflect real clinical work rather than administrative documentation alone.

Delays in New Authorization Requirements

In another update, CMS announced a delay in implementing prior authorization requirements under the WISeR Model for certain procedures, including treatments for Parkinson’s disease and spinal conditions. This gives healthcare providers additional time to prepare for potential future changes.

Emerging Drug Threats: New Risks in the Supply

Alongside policy discussions, the CDC issued a nationwide alert about medetomidine, a veterinary sedative increasingly found in the illicit drug supply.

Medetomidine is not approved for human use and can cause:

• Extreme sedation
• Slowed heart rate
• Dangerous drops in blood pressure
• Severe withdrawal symptoms

Because this substance is often combined with opioids like FYL, overdose situations may become more complex and harder to treat.

Why Naloxone Remains Critical

Even with the rise of new substances like XYL and medetomidine, Naloxone continues to be a vital, life-saving tool. It can reverse the opioid component of an overdose and restore breathing.

Health officials emphasize:

• Naloxone should be administered immediately in suspected overdoses
• Multiple doses may be required with potent synthetic opioids
• Emergency medical care is still essential after administration

Looking Ahead

While recent declines in overdose deaths offer hope, experts agree the fight is far from over. The evolving drug supply—now including substances like FYL, XYL, and medetomidine—demands a flexible, well-coordinated public health response.

Moving forward, priorities include:

• Expanding access to treatment and recovery services
• Supporting healthcare providers with balanced policies
• Increasing public awareness and overdose preparedness
• Ensuring widespread availability of Naloxone

The message from national health leaders is clear: progress is possible, but only through continued investment in compassionate, evidence-based care and a commitment to adapting as the crisis evolves.

Source: AMA